Imfinzi 120mg Injection

Dosage and duration of Imfinzi 120mg Injection are decided by the doctor based on the patient's health condition. It is advisable to take this medicine as prescribed by your medical practitioner and not skip your regular dosing schedule. It is necessary to inform your doctor if you have a history of cardiac disease or liver disease. Do not stop taking the medicine suddenly, unless your doctor tells you.

Durvalumab 120mg injection is given under the strict supervision of a doctor. Do not self-administer. Overdose is a very unusual state for this medicine because it is given under the supervision of a healthcare provider. The doctor will provide emergency medical treatment. To make it more effective, take a balanced diet and take an adequate amount of vitamins and minerals while on treatment with Imfinzi 120mg Injection.

• Inform your healthcare professional if you are planning to be pregnant, as taking Imfinzi 120mg Injection can harm the unborn fetus.
• Use reliable contraceptive or birth control methods to prevent pregnancy for 8 weeks before and after taking Imfinzi 120mg Injection.
• It is advised not to breastfeed while going through treatment.
• Wear sunscreen and sun barriers before moving outdoors, as Imfinzi 120mg Injection can increase the chances of skin damage from sunburn.
• If you experience any gastrointestinal symptoms after taking Imfinzi 120mg Injection, such as diarrhea, abdominal pain, or nausea, inform your doctor immediately. He may prescribe you antiemetic medicines to reduce these side effects.
  

1. Kalemkerian GP, et al. (2024).Treatment Options for Relapsed Small-Cell Lung Cancer: What Progress Have We Made? Journal of Oncology Practice,14(6), 369-370 - https://ascopubs.org/doi/10.1200/JOP.18.00278
2. Szumera-Ciećkiewicz A, et al. (2025). EGFR Mutation Testing on Cytological and Histological Samples in Non-Small Cell Lung Cancer: a Polish, Single Institution Study and Systematic Review of European Incidence. Int J Clin Exp Pathol. 2(6), 2800-12 - https://pmc.ncbi.nlm.nih.gov/articles/PMC3843260/
3. Keedy VL, et al. (2023). American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients with Advanced Non-Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy. J Clin Oncol. 29(3), 2121-27.
4. World Health Organization. (2024). International Agency for Research on Cancer. Available at http://globocan.iarc.fr/Pages/fact_sheets_population.aspx.
5. Bridgewater JA, Goodman KA, Kalyan A, Mulcahy MF. (2023). Biliary tract cancer: epidemiology, radiotherapy, and molecular profiling. Am Soc Clin Oncol Educ Book. 35(36), 194-203 - https://pubmed.ncbi.nlm.nih.gov/27249723/
6. Flemming JA, Zhang-Salomons J, Nanji S, Booth CM. (2022). Increased incidence but improved median overall survival for biliary tract cancers diagnosed in Ontario from a population-based study. Cancer. 122(16): 2534-2543. - https://pubmed.ncbi.nlm.nih.gov/27183133/
7. Kenmotsu H, Saito Y, Ninomiya K, Uematsu S, Akdemir B, Fukui A, Koto R, Fujiwara M, Iwao C, Kitagawa H, Yoshino I, Gemma A, Mitsudomi T, Yamamoto N. (2023). Long-Term Safety and Effectiveness of Durvalumab in Unresectable Stage III NSCLC in Japan: A Multicenter Prospective Study (AYAME). J Thorac Oncol. 4(45), 1556-0864(25)01014-7.
8. Zukin M, Gondim V, Shimada AK, Lima EMEA, Mathias C, Barra WF, William Junior WN, Padoan M, Bittencourt Y, Yamamura R, Silva CEB, Rossato LJ, Monteiro CA, Jesus RG, Gössling G, Gelatti ACZ. (2024). Durvalumab as consolidation therapy in patients who received chemoradiotherapy for unresectable stage III NSCLC: Real-world data from an expanded access program in Brazil (LACOG 0120). J Bras Pneumol, 50(6), 20240228.
9. Fan H, Guan S, Ren K, Li X, Wang J, Bi N, Zhao L.(2023). Impact of duration of maintenance immunotherapy on the prognosis of locally advanced non-small cell lung cancer treated with chemoradiotherapy. Front Oncol. 5(13),1580396 - https://pubmed.ncbi.nlm.nih.gov/40761248/